De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
CS Medica Inkomsten in het verleden
Verleden criteriumcontroles 0/6
CS Medica's earnings have been declining at an average annual rate of -50.2%, while the Pharmaceuticals industry saw earnings growing at 9.9% annually. Revenues have been growing at an average rate of 22.5% per year.
Belangrijke informatie
-50.2%
Groei van de winst
-55.0%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 30.5% |
| Inkomstengroei | 22.5% |
| Rendement op eigen vermogen | -676.9% |
| Nettomarge | -263.8% |
| Volgende winstupdate | 14 Nov 2024 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe CS Medica geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 5 | -12 | 14 | 0 |
| 31 Mar 24 | 5 | -13 | 16 | 0 |
| 31 Dec 23 | 3 | -14 | 16 | 0 |
| 30 Sep 23 | 1 | -15 | 17 | 0 |
| 30 Jun 23 | 10 | -11 | 16 | 0 |
| 31 Mar 23 | 11 | -11 | 17 | 0 |
| 31 Dec 22 | 11 | -12 | 18 | 0 |
| 30 Sep 22 | 11 | -11 | 17 | 0 |
| 30 Jun 22 | 4 | -10 | 14 | 0 |
| 31 Mar 22 | 3 | -5 | 9 | 0 |
| 31 Dec 21 | 3 | -2 | 5 | 0 |
| 30 Sep 21 | 3 | 1 | 2 | 0 |
| 30 Jun 21 | 1 | 0 | 2 | 0 |
| 30 Sep 20 | 2 | 0 | 1 | 0 |
| 30 Sep 19 | 1 | 0 | 0 | 0 |
Kwaliteitswinsten: CSMED is currently unprofitable.
Groeiende winstmarge: CSMED is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: CSMED is unprofitable, and losses have increased over the past 5 years at a rate of 50.2% per year.
Versnelling van de groei: Unable to compare CSMED's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: CSMED is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.5%).
Rendement op eigen vermogen
Hoge ROE: CSMED has a negative Return on Equity (-676.93%), as it is currently unprofitable.